CD44 and melanoma: A number of research groups have shown that CD44-targeted nanoparticles could be effectively bound onto CD44 overexpressed tumor cells such as HA/PEG-Gelatin/EGCG NPs for treatment of prostate tumor39, HA-coated chitosan NPs for anticancer drug delivery57, HA on monodisperse magnetite nanocrystals for targeted cancer imaging58, and nanographene oxide-HA conjugate for photothermal therapy of melanoma skin cancer59.